Novartis Ag (NVS) Gains from Investment Securities (2023 - 2024)

Novartis Ag (NVS) posted Gains from Investment Securities of $65.0 million for Q1 2024, little changed sequentially from $65.0 million in Q4 2023.

Novartis Ag (NVS) Gains from Investment Securities (2023 - 2024) Analysis & Trends

Novartis Ag has reported Gains from Investment Securities for 2 years, with the latest figure at $65.0 million in Q1 2024.

Quarterly Gains from Investment Securities changed N/A year-over-year to $65.0 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $65.0 million (changed N/A YoY) and the FY2023 annual result came in at $65.0 million, changed N/A from the prior year.
Gains from Investment Securities was little changed at $65.0 million in Q1 2024 per NVS's latest filing, from $65.0 million in the prior quarter.
Over five years, Gains from Investment Securities peaked at $65.0 million in Q4 2023 and troughed at $65.0 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn

Download Data